SCHEMBL3397689

SCHEMBL3397689

CC(C)(C)OC(=O)N(Cc1ccccc1)[C@@H](CO)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
HSD17B10 Q99714 1/20 0.48
AKT1 P31749 3/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
NCOR2 Q9Y618 1/20 0.43
CTSL P07711 2/20 0.43
CTSB P07858 2/20 0.43
CTSS P25774 2/20 0.43
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA4 P43681 1/20 0.39
RIPK1 Q13546 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20576145 1.00 L3MBTL1 (0.48) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL9124694 1.00 L3MBTL1 (0.48) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL8656303 0.91 L3MBTL1 (0.41) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL18359864 0.89 ALDH1A1 (0.48) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL8472422 0.89 ALDH1A1 (0.48) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL8472423 0.89 ALDH1A1 (0.48) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL6513912 0.89 L3MBTL1 (0.42) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL11018000 0.88 L3MBTL1 (0.47) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL7276228 0.88 L3MBTL1 (0.47) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL9807251 0.88 L3MBTL1 (0.47) L3MBTL1ALDH1A1LMNAPOLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12625431-B2 EUV resist underlayer film-forming composition NISSAN CHEMICAL CORPORATION (JP) 2026-05-12 US disclosed
EP-4222158-A1 N4-HYDROXYCYTIDINE DERIVATIVES AND USE THEREOF AS ANTIVIRAL AGENT Ascletics Bioscience Co., Ltd. (CN) 2023-08-09 EP disclosed
WO-2023111683-A1 N4-HYDROXYCYTIDINE DERIVATIVES AND USE THEREOF AS ANTIVIRAL AGENT ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-06-22 WO disclosed
US-20230098881-A1 EUV RESIST UNDERLAYER FILM-FORMING COMPOSITION NISSAN CHEMICAL CORPORATION (JP) 2023-03-30 US disclosed
EP-4013499-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN GILEAD SCIENCES, INC. (US) 2022-06-22 EP disclosed
WO-2021030438-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN GILEAD SCIENCES, INC. (US) 2021-02-18 WO disclosed
EP-3197880-B1 SUBSTITUTED OXOPYRIDINE DERIVATIVES WITH ANTI-INFLAMMATORY AND ANTI-THROMBOTIC EFFECT Bayer Pharma AG (DE) 2018-10-24 EP disclosed
EP-2678349-A1 C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2014-01-01 EP disclosed
WO-2012115256-A1 C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-08-30 WO disclosed
US-7649015-B2 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds GILEAD SCIENCES, INC. (US) 2010-01-19 US disclosed
US-20050209197-A1 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds GILEAD SCIENCES, INC. 2005-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209197-A1 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds PPA1, PPME1, PNP L3MBTL1 807/4885ALDH1A1 3361/4885LMNA 2684/4885
US-12625431-B2 EUV resist underlayer film-forming composition EEF1A1, ARF1, EMG1 L3MBTL1 1093/4885ALDH1A1 2046/4885LMNA 2754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.